This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases. plan a, plan b, … charter flight standby option).
Study data is always subject to scrutiny by regulators, which further highlights its importance. Given the industry is a highly regulated one, there are always new regulations being issued. Given these regulations are not new, it is strange that industry has not prompted a complete solution to this already.
IRT solutions help clinical trial sponsors meet the complexities of patient randomization and clinicalsupply management. He also shared how modern software development concepts are impacting IRT platforms and transforming the user experience in clinical trials. This ultimately helps to get medicines to the market faster.
Study data is always subject to scrutiny by regulators, which further highlights its importance. Given the industry is a highly regulated one, there are always new regulations being issued. Given these regulations are not new, it is strange that industry has not prompted a complete solution to this already.
Study data is always subject to scrutiny by regulators, which further highlights its importance. Given the industry is a highly regulated one, there are always new regulations being issued. Given these regulations are not new, it is strange that industry has not prompted a complete solution to this already.
Study data is always subject to scrutiny by regulators, which further highlights its importance. Given the industry is a highly regulated one, there are always new regulations being issued. Given these regulations are not new, it is strange that industry has not prompted a complete solution to this already.
Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharma companies can correctly harness, will turn the continent into a superpower for clinical trials. They need to have that assistance of access to clinical trials.”
XTALKS WEBINAR: Fostering Patient-Centricity: ClinicalSupply Chain Strategies and Sourcing Solutions Live and On-Demand: Thursday, July 20, 2023, at 10am EDT (4pm CEST/EU-Central) Register for this free webinar to learn how to review clinical trial trends and supply strategies that impact the patient experience.
Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.
Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Persons”, as such term is defined in Regulations under the U.S. About PharmaDrug Inc.
The global oncology clinical trials market is projected to grow at a 5.28% CAGR from 2025 to 2034, while the number of rare disease trials continues to expand due to increased investment in precision medicine.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content